AU601167B2 - Pharmaceutical compositions containing N,N-dimethyl-1-(1- (4-chlorophenyl)-cyclobutyl)-3-methylbutylamine hydrochloride monohydrate - Google Patents

Pharmaceutical compositions containing N,N-dimethyl-1-(1- (4-chlorophenyl)-cyclobutyl)-3-methylbutylamine hydrochloride monohydrate Download PDF

Info

Publication number
AU601167B2
AU601167B2 AU66442/86A AU6644286A AU601167B2 AU 601167 B2 AU601167 B2 AU 601167B2 AU 66442/86 A AU66442/86 A AU 66442/86A AU 6644286 A AU6644286 A AU 6644286A AU 601167 B2 AU601167 B2 AU 601167B2
Authority
AU
Australia
Prior art keywords
dimethyl
water
chlorophenyl
hydrochloride
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired, expires
Application number
AU66442/86A
Other languages
English (en)
Other versions
AU6644286A (en
Inventor
James Edward Jeffery
Derek Whybrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Boots Co PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10589895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU601167(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boots Co PLC filed Critical Boots Co PLC
Publication of AU6644286A publication Critical patent/AU6644286A/en
Application granted granted Critical
Publication of AU601167B2 publication Critical patent/AU601167B2/en
Assigned to KNOLL AKTIENGESELLSCHAFT reassignment KNOLL AKTIENGESELLSCHAFT Alteration of Name(s) in Register under S187 Assignors: BOOTS COMPANY PLC, THE
Assigned to ABBOTT GMBH & CO. KG reassignment ABBOTT GMBH & CO. KG Request to Amend Deed and Register Assignors: KNOLL AKTIENGESELLSCHAFT
Adjusted expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU66442/86A 1985-12-17 1986-12-11 Pharmaceutical compositions containing N,N-dimethyl-1-(1- (4-chlorophenyl)-cyclobutyl)-3-methylbutylamine hydrochloride monohydrate Expired AU601167B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8531071 1985-12-17
GB858531071A GB8531071D0 (en) 1985-12-17 1985-12-17 Therapeutic compound

Publications (2)

Publication Number Publication Date
AU6644286A AU6644286A (en) 1987-06-18
AU601167B2 true AU601167B2 (en) 1990-09-06

Family

ID=10589895

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66442/86A Expired AU601167B2 (en) 1985-12-17 1986-12-11 Pharmaceutical compositions containing N,N-dimethyl-1-(1- (4-chlorophenyl)-cyclobutyl)-3-methylbutylamine hydrochloride monohydrate

Country Status (34)

Country Link
US (2) US4929629A (enExample)
EP (1) EP0230742B1 (enExample)
JP (1) JPS62155240A (enExample)
KR (1) KR940008913B1 (enExample)
CN (1) CN1016245B (enExample)
AT (1) ATE56942T1 (enExample)
AU (1) AU601167B2 (enExample)
CA (1) CA1266278A (enExample)
CS (1) CS259545B2 (enExample)
DD (1) DD263050A5 (enExample)
DE (1) DE3674570D1 (enExample)
DK (1) DK170770B1 (enExample)
EG (1) EG17770A (enExample)
ES (1) ES2018163T4 (enExample)
FI (1) FI90413C (enExample)
GB (1) GB8531071D0 (enExample)
GE (1) GEP19970812B (enExample)
GR (1) GR3001069T3 (enExample)
HU (1) HU201901B (enExample)
IE (1) IE59429B1 (enExample)
IL (1) IL80934A (enExample)
IN (1) IN163129B (enExample)
LU (1) LU90865I2 (enExample)
MX (1) MX4684A (enExample)
NL (1) NL300065I1 (enExample)
NO (2) NO165540C (enExample)
NZ (1) NZ218578A (enExample)
PH (1) PH22481A (enExample)
PL (1) PL149519B1 (enExample)
PT (1) PT83958B (enExample)
SU (1) SU1443796A3 (enExample)
UA (1) UA7206A1 (enExample)
YU (1) YU46033B (enExample)
ZA (1) ZA869078B (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
EP0647134A4 (en) * 1992-06-23 1997-07-30 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING DEPRESSION AND OTHER DISEASES USING OPTICALLY PURE SIBUTRAMINE.
WO1994000047A1 (en) * 1992-06-23 1994-01-06 Sepracor Inc. Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE4443891A1 (de) * 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
AU2730800A (en) * 1999-01-20 2000-08-07 Abbott Laboratories Method to aid smoking cessation
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
CZ298293B6 (cs) 1999-03-19 2007-08-15 Abbott Gmbh & Co. Kg Léčivo pro léčení poruch spánku
WO2000056310A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
AU3899100A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
AU3894500A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Prevention of cardiovascular disease
WO2000056309A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Method of treating sexual dysfunction
US6403650B1 (en) 1999-03-19 2002-06-11 Knoll Pharmaceutical Company Treatment of pulmonary hypertension
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
WO2000056319A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of orthostatic hypotension
AU3895400A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Control of metabolism
AU3896900A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of pain
IL145238A0 (en) * 1999-03-19 2002-06-30 Knoll Gmbh Treatment of osteoarthritis
CN1399545A (zh) * 1999-03-19 2003-02-26 克诺尔股份有限公司 治疗某些与体重增加有关的癌症
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
PE20011061A1 (es) 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
PE20011065A1 (es) 2000-02-01 2001-11-21 Procter & Gamble Proceso para fabricar bisfosfonatos geminales
US6232347B1 (en) 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
US6610887B2 (en) * 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
JP3813152B2 (ja) * 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
KR100536750B1 (ko) * 2002-10-05 2005-12-16 한미약품 주식회사 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
JP4278652B2 (ja) * 2002-10-05 2009-06-17 ハンミ ファーム． シーオー．， エルティーディー． 結晶性シブトラミンメタンスルホン酸塩半水和物を含む医薬組成物
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
GB0310361D0 (en) * 2003-05-06 2003-06-11 Cipla Ltd Pharmaceutical compound
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
KR20070084455A (ko) * 2004-11-23 2007-08-24 워너-램버트 캄파니 엘엘씨 지질혈증 치료용 ｈｍｇ ｃｏ-ａ 환원효소 억제제로서의7-(2ｈ-피라졸-3-일)-3,5-디히드록시-헵탄산 유도체
EP1846359A4 (en) 2005-01-06 2010-03-31 Cj Cheiljedang Corp INORGANIC ACID SALTS OF SIBUTRAMINE
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
KR100781882B1 (ko) * 2005-07-12 2007-12-05 주식회사유한양행 시부트라민을 함유하는 약제학적 조성물
US20080269233A1 (en) * 2005-08-04 2008-10-30 Mark David Andrews Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds
US20090203738A1 (en) * 2005-09-22 2009-08-13 Eisai R&D Management Co., Ltd. Pharmaceutical Composition for Treating Bulimia and Depression Arising from Bulimia
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8138188B2 (en) * 2006-02-23 2012-03-20 Pfizer Inc. Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
EP2066329B1 (en) 2006-09-15 2017-09-06 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cyclobutylmethylamines
EP2084127A1 (en) 2006-11-13 2009-08-05 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
EP2099755A2 (en) * 2006-11-20 2009-09-16 Glenmark Pharmaceuticals S.A. Acetylene derivatives as stearoyl coa desaturase inhibitors
EP2094643B1 (en) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US20080221057A1 (en) * 2007-02-16 2008-09-11 Wyeth Secreted protein ccdc80 regulates adipocyte differentiation
US20080248115A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
KR101280786B1 (ko) * 2008-08-06 2013-07-05 화이자 리미티드 멜라노코르틴 4 작용제로서 다이아제핀 및 다이아조칸 화합물
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US20120053172A1 (en) 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
NZ599945A (en) 2009-11-02 2014-05-30 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
TR201802207T4 (tr) 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
SA111320581B1 (ar) 2010-07-06 2014-06-17 استرازينيكا ايه بي مركبات (3-(4-(أمينو ميثيل ) فينوكسي أو فينيل ثيو) أزيتيدين -1- يل) (5- فينيل -1، 3، 4- أوكسا ديازول -2- يل) ميثانون
RS57778B1 (sr) 2010-11-04 2018-12-31 Albireo Ab Inhibitori crevnog transportera žučne kiseline (ibat) za lečenje bolesti jetre
KR101890960B1 (ko) 2010-11-08 2018-09-28 알비레오 에이비 Ⅰｂａｔ 억제제 및 담즙산 바인더를 포함하는 약학적 조합물
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
CN110372522B (zh) * 2019-07-30 2020-10-02 南京工业大学 一种从含有戊二胺的固相中汽提回收戊二胺的方法
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8221382A (en) * 1981-04-06 1982-10-14 Abbott Gmbh & Co. Kg (phenylcyclobutyl)alkyl amines and amides as anti- depressants; intermediate ketones and nitriles
AU1922483A (en) * 1982-09-30 1984-04-12 Boots Company Plc, The Substituted aryl cyclobutyl amines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1124485B (de) * 1960-02-12 1962-03-01 Hoechst Ag Verfahren zur Herstellung von analeptisch wirksamen Phenylcycloalkylmethylaminen
SE7600674L (sv) * 1975-02-05 1976-08-06 Rohm & Haas Fungicider
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
GB2115409B (en) * 1982-02-24 1985-08-07 Zyma Sa Novel crystal modifications of (+)-catechin
DK101683A (da) * 1982-03-12 1983-09-13 Duphar Int Res Phenylpiperazinderivater og fremgangsmaade til fremstilling heraf
IE56001B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylmethylamine compounds
ZA836848B (en) * 1982-09-30 1984-05-30 Boots Co Plc Therapeutic agents
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8221382A (en) * 1981-04-06 1982-10-14 Abbott Gmbh & Co. Kg (phenylcyclobutyl)alkyl amines and amides as anti- depressants; intermediate ketones and nitriles
GB2098602A (en) * 1981-04-06 1982-11-24 Boots Co Plc Therapeutic agents
AU1922483A (en) * 1982-09-30 1984-04-12 Boots Company Plc, The Substituted aryl cyclobutyl amines

Also Published As

Publication number Publication date
GEP19970812B (en) 1997-02-10
SU1443796A3 (ru) 1988-12-07
JPH0144176B2 (enExample) 1989-09-26
EG17770A (en) 1991-03-30
ZA869078B (en) 1987-07-29
MX4684A (es) 1993-12-01
DK170770B1 (da) 1996-01-15
FI865030L (fi) 1987-06-18
NO865093L (no) 1987-06-18
IE863102L (en) 1987-06-17
CN86108547A (zh) 1987-08-19
EP0230742A1 (en) 1987-08-05
DD263050A5 (de) 1988-12-21
YU205086A (en) 1987-12-31
CN1016245B (zh) 1992-04-15
ATE56942T1 (de) 1990-10-15
YU46033B (sh) 1992-12-21
PL149519B1 (en) 1990-02-28
JPS62155240A (ja) 1987-07-10
NL300065I1 (nl) 2001-12-01
FI90413B (fi) 1993-10-29
IL80934A (en) 1990-07-26
KR870005961A (ko) 1987-07-08
DK585786A (da) 1987-06-18
PL263020A1 (en) 1988-05-12
PT83958B (pt) 1989-05-12
GB8531071D0 (en) 1986-01-29
ES2018163B3 (es) 1991-04-01
ES2018163T4 (es) 2012-06-14
AU6644286A (en) 1987-06-18
GR3001069T3 (en) 1992-03-20
NZ218578A (en) 1989-04-26
US4929629A (en) 1990-05-29
NO2005022I1 (no) 2005-10-03
EP0230742B1 (en) 1990-09-26
DE3674570D1 (de) 1990-10-31
IE59429B1 (en) 1994-02-23
FI90413C (fi) 1994-02-10
HUT45964A (en) 1988-09-28
LU90865I2 (fr) 2002-02-18
NO865093D0 (no) 1986-12-16
NO165540C (no) 1991-02-27
HU201901B (en) 1991-01-28
PH22481A (en) 1988-09-12
FI865030A0 (fi) 1986-12-10
NO165540B (no) 1990-11-19
DK585786D0 (da) 1986-12-05
IN163129B (enExample) 1988-08-13
PT83958A (en) 1987-01-01
CS259545B2 (en) 1988-10-14
CA1266278A (en) 1990-02-27
CS930586A2 (en) 1988-02-15
UA7206A1 (uk) 1995-06-30
KR940008913B1 (ko) 1994-09-28
US5068440A (en) 1991-11-26

Similar Documents

Publication Publication Date Title
AU601167B2 (en) Pharmaceutical compositions containing N,N-dimethyl-1-(1- (4-chlorophenyl)-cyclobutyl)-3-methylbutylamine hydrochloride monohydrate
DE2059618C3 (de) M-halogen-(alpha) -t-butylaminopropiophenone und deren salze, herstellungsverfahren und pharmazeutische zubereitung
DE1964516C3 (de) 1-Substituierte 3-Propionyl-anilinopyrrolidine, Verfahren zu ihrer Herstellung und Arzneimittel
US2997470A (en) Lysergic acid amides
CA1130800A (en) N-SUBSTITUTED .omega.-AMINOALKANOYL-.omega.-AMINOALKANOIC ACIDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION AS WELL AS PHARMACEUTICAL PRODUCTS CONTAINING THESE COMPOUNDS
EP0008715B1 (de) Phenyläthanolamine zur Verwendung bei der Bekämpfung von entzündlichen Zuständen
CN1073104C (zh) N－(4－乙酰基－1－哌嗪基)－4－氟苯酰胺的水合物
CA1097684A (fr) PROCEDE DE PREPARATION D'ACIDES.gamma.ARYL .gamma.OXO ISOVALERIQUES
US2917536A (en) Aminoalkyldicyclopropylalkynols
HUT75341A (en) New salts of 2-[(2,6-dichloro-phenyl)-amino]-phenyl-acetoxy-acetic acid with organic bases, pharmaceutical compns. contg. them and process for preparing the said compds.
US2734014A (en) Glucoside colchicoside and a method of
US4031303A (en) Steryl-β-D-glucoside esters and method of preparation
CN111320602A (zh) 九香虫多巴胺类新化合物制备方法及抗睾丸细胞损伤应用
JPH01246299A (ja) エルゴステロール誘導体およびその製法
DE3218743A1 (de) Isoprenylaminderivate und saeureadditionssalze davon
DE69929315T2 (de) Kristalline formen von 1s-ä1alpha(2s*,3r*),9alphaü-6,10-dioxo-n- (2-ethoxy-5-oxo-tetrahydro-3-furanyl)-9-ää(1-isochinolyl)carbonylü- aminoüoctahydro-6h-piridazinoä1,2-aüä1,2üdiazepin-1-carboxyamid
Watson et al. The Isolation of Crystalline i-Urobilinogen (Mesobilirubinogen) from Feces: COMPARISON WITH CRYSTALLINE d-UROBILINOGEN (H44) AND SEPARATION OF NATURAL i-UROBILIN INTO OPTICALLY ACTIVE COMPONENTS
CN107746422A (zh) 麦角甾‑7，22‑二烯‑3‑酮缩氨硫腙及其制备方法和在制备抗菌药物中的应用
SI8612050A8 (sl) Nova nehigroskopična oblika n,n-dimetil-1-1-(4-klorofenil) ciklobutil -3-metilbutilamin klorhidrata
JPH04208245A (ja) テルペン誘導体の抽出法及び製造法
DE2345442C2 (de) d- und l-Phenyläthanolamine und deren Salze, Herstellungsverfahren und Arzneimittel auf deren Basis
JPH04208244A (ja) テルペン誘導体の抽出法及び製造法
JPS62281863A (ja) 二環式ラクタム、製薬学的組成物及びその製造法
JPH01165587A (ja) テルペン化合物及びその製造法
JPH01213229A (ja) モノアミンオキシダーゼ阻害剤

Legal Events

Date Code Title Description
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE

Extension date: 20111211

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE

Extension date: 20111211

HB Alteration of name in register

Owner name: ABBOTT GMBH AND CO. KG

Free format text: FORMER NAME WAS: KNOLL AG